<DOC>
	<DOCNO>NCT00224081</DOCNO>
	<brief_summary>This study explore safety efficacy intravenous iron therapy anemic hemodialysis patient treat epoetin alfa , high serum ferritin level , low normal transferrin saturation .</brief_summary>
	<brief_title>DRIVE Trial ( Dialysis Patients ' Response Intravenous IV Iron With Elevated Ferritin )</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Ferric gluconate</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Chronic hemodialysis Elevated serum ferritin low normal transferrin saturation ( TSAT ) Moderate severe anemia Receiving epoetin alfa treatment Known sensitivity FerrlecitÂ® Medical condition would confound efficacy evaluation Recent blood transfusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>iron deficiency anemia</keyword>
	<keyword>ferritin</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>sodium ferric gluconate</keyword>
	<keyword>epoetin alfa</keyword>
</DOC>